4baseCare Secures $15.3M for Global Cancer Testing Expansion
Precision oncology startup 4baseCare has raised Rs 128 crore ($15.3 million) in a funding round led by growX Ventures and Infosys. The capital will expand its genomics labs globally and scale its AI oncology platform, aiming to make precision cancer testing more inclusive for under-represented populations worldwide.
Key points
- Precision oncology firm 4baseCare secured Rs 128 crore ($15.3 million) in a funding round.
- The investment was led by growX Ventures and Infosys, with participation from existing investors.
- Funds will be used to expand global genomics laboratory networks and scale its AI-led oncology platform, OncoTwin.
- 4baseCare aims to increase inclusivity in precision oncology, focusing on under-represented populations in India, the Middle East, Southeast Asia, and Latin America.
- The company plans to expand its operations from current labs in India, Dubai, Nepal, and the Philippines into 8-10 additional countries in the next 12-18 months.
Precision oncology startup 4baseCare announced it has closed a funding round totaling Rs 128 crore (approximately $15.3 million). The round was led by growX Ventures and included investment from Infosys, alongside contributions from existing backers. This capital infusion follows an earlier Rs 90 crore from other investors.
The Bengaluru-based company plans to utilize the new funds to significantly expand its global network of genomics laboratories. Additionally, the capital will support the scaling of its artificial intelligence-driven oncology platform, named OncoTwin. This expansion aims to enhance the reach and inclusivity of precision cancer testing, particularly for populations historically under-represented in genomic data.
Founded in 2019, 4baseCare focuses on developing genomics-driven cancer diagnostics and AI-powered clinical decision support tools. The company currently operates laboratories in India, Dubai, Nepal, and the Philippines. Its strategic goal is to decentralize genomic testing infrastructure and broaden access to personalized cancer treatment in regions like India, the Middle East, Southeast Asia, and Latin America, with plans to enter 8-10 new countries within the next 12 to 18 months.
Sources
The WireByte editorial team synthesises technology news from multiple primary sources, verifies the facts, and links every source. Articles are produced with AI assistance and reviewed under our editorial policy.